The main problem is that there is no effective strategy to control biofilm formation, and as a result biofilm associated infections (BAI) cannot be prevented or treated adequately.
For implant-associated biofilm infections the current treatment strategies are based on the administration of antibiotics. These antibiotics are administered systemically or locally through polymeric drug delivery systems. These treatment strategies are inadequate mainly because of,
Thus, even when an antimicrobial agent is available it is difficult to target the infection because the local delivery of the agent is insufficient as currently available polymeric drug delivery systems do not overcome these problems because the release rate of the agent cannot be controlled.
Approximately 3% of all patients receiving implants develop biofilm associated infections, and treatment of these infections is unsuccessful in up to 32 to 82% of the cases, resulting in chronic infection and inflammation. Moreover, since the number of required long term systemic therapies with conventional antibiotics in BAI remains high, resistance towards these antibiotics will increasingly develop. This contributes to the worldwide problem of antimicrobial resistance.
To address the problem of biofilm infection, the objectives of project BALI are based on two pillars:
Thus, the overall objective of project BALI is:
To develop a unique combination of immune orchestrating synthetic antimicrobial and antibiofilm peptides (SAAPs) incorporated in novel controlled release drug delivery formulations that can control biofilm infections.